Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.

Arzneimittel-Forschung-Drug Research Pub Date : 2012-08-01 Epub Date: 2012-06-21 DOI:10.1055/s-0032-1312601
D A A El Ella, K A Saleh, M Hassan, N Hamdy, M E El-Araby, K A M Abouzid
{"title":"Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.","authors":"D A A El Ella,&nbsp;K A Saleh,&nbsp;M Hassan,&nbsp;N Hamdy,&nbsp;M E El-Araby,&nbsp;K A M Abouzid","doi":"10.1055/s-0032-1312601","DOIUrl":null,"url":null,"abstract":"<p><p>4-Anilinoquinazoline is a privileged scaffold in developing small molecule inhibitors of tyrosine kinases (TK) especially epidermal growth factor receptor (EGFR). 2 series belonging to 3'-substituted-4-anilinoquinazoline scaffold were synthesized and screened in vitro on isolated and a breast cancer cell line. The research aims at exploring the activity of compounds having diverse substituents at 3' position of the aniline moiety. Generally, the meta-substituted-anilinoquinazolines exhibited significant inhibitory activity against isolated enzyme as well as MCF-7 cancer cell line. For instance, compound 10b inhibited >99% of EGFR activities at 10 µM concentration. 6 of the tested compounds exhibited range of anti-proliferative activity below 10 µM potency. In particular, compounds 6e and 10b displayed the highest activity among the tested compounds with IC50 values equal to 8.6 and 4.84 µM, respectively. Structure-based tools were utilized to rationalize EGFR-TK binding of compound 10b since it is the most active compound in the enzyme inhibition test.</p>","PeriodicalId":56084,"journal":{"name":"Arzneimittel-Forschung-Drug Research","volume":"62 8","pages":"360-6"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0032-1312601","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arzneimittel-Forschung-Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/s-0032-1312601","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/6/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

4-Anilinoquinazoline is a privileged scaffold in developing small molecule inhibitors of tyrosine kinases (TK) especially epidermal growth factor receptor (EGFR). 2 series belonging to 3'-substituted-4-anilinoquinazoline scaffold were synthesized and screened in vitro on isolated and a breast cancer cell line. The research aims at exploring the activity of compounds having diverse substituents at 3' position of the aniline moiety. Generally, the meta-substituted-anilinoquinazolines exhibited significant inhibitory activity against isolated enzyme as well as MCF-7 cancer cell line. For instance, compound 10b inhibited >99% of EGFR activities at 10 µM concentration. 6 of the tested compounds exhibited range of anti-proliferative activity below 10 µM potency. In particular, compounds 6e and 10b displayed the highest activity among the tested compounds with IC50 values equal to 8.6 and 4.84 µM, respectively. Structure-based tools were utilized to rationalize EGFR-TK binding of compound 10b since it is the most active compound in the enzyme inhibition test.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
取代苯胺类喹唑啉的合成、抗增殖活性及其与EGFR抑制的关系。
4-苯胺喹啉是开发酪氨酸激酶(TK)尤其是表皮生长因子受体(EGFR)小分子抑制剂的理想支架。合成了2个系列的3′-取代-4-苯胺喹啉支架,并在分离的乳腺癌细胞系和体外筛选。本研究旨在探讨苯胺部分3′位置具有不同取代基的化合物的活性。一般来说,间位取代苯胺喹唑啉对分离酶和MCF-7癌细胞具有显著的抑制活性。例如,化合物10b在10µM浓度下抑制了>99%的EGFR活性。6个化合物的抗增殖活性范围小于10µM效价。其中化合物6e和10b活性最高,IC50值分别为8.6和4.84µM。由于化合物10b是酶抑制试验中活性最高的化合物,我们利用基于结构的工具来合理化化合物10b与EGFR-TK的结合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
4-8 weeks
期刊最新文献
[Vitamin B12]. Ibudilast, a phosphodiesterase inhibitor, in combination with low-dose aspirin potently inhibits guinea pig carotid artery thrombosis without extending bleeding time and causing gastric mucosal injury. Virtual screening and synthesis of new chemical scaffolds as VEGFR-2 kinase inhibitors. Pharmacokinetics and safety of eszopiclone in healthy Chinese volunteers. Pharmacokinetics and bioequivalence evaluation of two brands of ciprofloxacin 500 mg tablets in Iranian healthy volunteers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1